Spots Global Cancer Trial Database for Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome

Official Title: SHP2 as a Therapeutic Target For Myelodysplastic Syndrome: Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome

Study ID: NCT01009502

Conditions

Myelodysplastic Syndromes

Interventions

sodium stibogluconate

Study Description

Brief Summary: Sodium stibogluconate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This was originally designed as a phase I/II trial studying the side effects of sodium stibogluconate and how well it works in treating patients with myelodysplastic syndromes. Unfortunately, due to funding issues, the phase II portion was never conducted.

Detailed Description: Patients receive sodium stibogluconate IV over 30 minutes on days 1-5 and 15-19. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients who respond to treatment may continue therapy until disease progression. Patients undergo bone marrow aspiration, biopsy, and peripheral blood sample collection periodically for correlative laboratory studies. After completion of study treatment, patients are followed up at 8 weeks. The phase II portion of this trial was never conducted due to lack of funding.